Aurobindo Pharma Launches Generic Advair Diskus in the US
Lannett Company LLC, an Aurobindo Pharma subsidiary, launched a generic Advair Diskus in the US on Aug. 31, 2026 in 100/50 mcg and 250/50 mcg strengths for asthma and COPD, marking the first product from Aurobindo’s inhalation pipeline. The company also disclosed a US FDA inspection of an associated Apitoria Pharma facility with three observations, relevant to broader US regulatory standing.
Coverage (10)
- Aurobindo Pharma Launches Generic Advair Diskus in US (themachinemaker.com)
- Aurobindo Pharma launches generic Advair Diskus for asthma and COPD in US (economictimes.com)
- Aurobindo Pharma Launches Fluticasone-Salmeterol Generic Advair Diskus in US (medicaldialogues.in)
- Aurobindo Pharma subsidiary launches generic Advair Diskus in US (indianpharmapost.com)
- Aurobindo Pharma arm launches generic version of Advair Diskus in US (moneycontrol.com)
- Aurobindo launches generic copy of asthma therapy Advair in US (pharma.economictimes.indiatimes.com)
- Aurobindo Pharma gains as its arm launches generic equivalent of Advair Diskus in US market (investmentguruindia.com)
- Aurobindo Pharma Completes Unit-VI USFDA Inspection and Launches First US Inhalation Product (sahi.com)
- Aurobindo launches generic Advair Diskus in US market (scanx.trade)
- Aurobindo Pharma Gets USFDA Approval for Extended (scanx.trade)